Roger Susi Sells 4,411 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 4,411 shares of iRadimed stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $83.92, for a total value of $370,171.12. Following the completion of the sale, the chief executive officer directly owned 2,180,000 shares of the company’s stock, valued at $182,945,600. The trade was a 0.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Price Performance

Shares of IRMD traded up $0.52 during trading hours on Wednesday, hitting $85.27. The stock had a trading volume of 71,131 shares, compared to its average volume of 86,931. iRadimed Corporation has a 12 month low of $50.88 and a 12 month high of $107.90. The firm has a market capitalization of $1.09 billion, a PE ratio of 46.60 and a beta of 0.90. The stock has a fifty day moving average price of $94.77 and a 200 day moving average price of $94.62.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, topping the consensus estimate of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The company had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, analysts anticipate that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date is Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is 43.72%.

Hedge Funds Weigh In On iRadimed

Several large investors have recently made changes to their positions in IRMD. T. Rowe Price Investment Management Inc. lifted its position in shares of iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after acquiring an additional 205,783 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of iRadimed by 37.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after acquiring an additional 55,426 shares in the last quarter. Informed Momentum Co LLC purchased a new position in shares of iRadimed in the fourth quarter valued at about $5,361,000. SG Americas Securities LLC lifted its position in shares of iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after acquiring an additional 33,072 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of iRadimed by 473.9% in the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after acquiring an additional 29,010 shares in the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IRMD has been the topic of several analyst reports. Roth Mkm reiterated a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 6th. Finally, Lake Street Capital reiterated a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.